Issue navigation
Volume 3, Issue Supplement_2, July 2021
Abstracts from the Society for Neuro-Oncology’s Basic and Translational Omics of Brain Tumors and Their Microenvironment Conference
Supplement Abstracts
Final Category: Computational and Statistical Approaches for Omics
CSAO-1. Interrogative Biology: Unraveling insights into causal disease drivers by use of a dynamic systems biology and Bayesian AI to identify the intersect of disease and healthy signatures
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii1, https://doi.org/10.1093/noajnl/vdab070.001
ECOA-2. Immuno-sensitization of Glioblastoma to NY-ESO-1 Targeting via Promoter Demethylation
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii1, https://doi.org/10.1093/noajnl/vdab070.002
ECOA-3. MLL4, UTX, and EZH2 regulate the expression of transcription factors associated with the epithelial-to-mesenchymal transition of lung cancer during metastasis to the brain at posttranscriptional steps
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii1, https://doi.org/10.1093/noajnl/vdab070.003
ECOA-4. Hypoxia alters the DNA methylation profile of glioblastoma tumor cells
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii1–ii2, https://doi.org/10.1093/noajnl/vdab070.004
ECOA-5. Integrative 3D spatial characterization of genomic and epigenomic intratumoral heterogeneity in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii2, https://doi.org/10.1093/noajnl/vdab070.005
ECOA-6. Genomic and transcriptomic analyses reveal diverse mechanisms responsible for deregulation of epigenetic enzyme/modifier expression in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii2, https://doi.org/10.1093/noajnl/vdab070.006
ECOA-7. Conserved cell-lineage controlled chromatin accessibility in human and mouse glioblastoma stem cells predicts functionally distinct subgroups
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii2, https://doi.org/10.1093/noajnl/vdab070.007
ECOA-8. Lung adenocarcinoma brain metastasis prediction using tumor DNA methylation profiling
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii2, https://doi.org/10.1093/noajnl/vdab070.008
ECOA-9. Integration of molecular and methylation classifications yields three meningioma groups and suggests chromosome 1p loss may be critical to the aggressive group
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii3, https://doi.org/10.1093/noajnl/vdab070.009
ECOA-10. Integrated genomic and clinical analysis of BRAF-mutated glioma in adults
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii3, https://doi.org/10.1093/noajnl/vdab070.010
Final Category: Multi-omics
MOMC-1. Employing the Zika Virus to kill paediatric nervous system tumour cells
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii3, https://doi.org/10.1093/noajnl/vdab070.011
MOMC-2. Glioblastoma Metabolic Symbiosis: When Lactate Takes The Lead
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii3, https://doi.org/10.1093/noajnl/vdab070.012
MOMC-3. Hypermethylation and overexpression of HOX genes are poor prognosticators in Lower-Grade Glioma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii4, https://doi.org/10.1093/noajnl/vdab070.013
MOMC-4. Proteogenomic and metabolomic characterization of glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii4, https://doi.org/10.1093/noajnl/vdab070.014
MOMC-5. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii4, https://doi.org/10.1093/noajnl/vdab070.015
Final Category: Next Generation Methods and Approaches
NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii4, https://doi.org/10.1093/noajnl/vdab070.016
NGMA-2. Dual sgRNA-directed PD-L1 knockout in human glioblastoma cells using the CRISPR/Cas9 system
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii4–ii5, https://doi.org/10.1093/noajnl/vdab070.017
NGMA-3. Use of multi-omics data to initialize and validate a causal model of glioblastoma stem cell signaling
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii5, https://doi.org/10.1093/noajnl/vdab070.018
NGMA-4. Creation of a MADR brain tumor single-cell atlas for examination of inter-/intratumor heterogeneity and the results of genetic perturbations in a diverse array of brain tumor subtypes
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii5, https://doi.org/10.1093/noajnl/vdab070.019
NGMA-5. An in vivo functional genomics screen to identify novel drivers of lung-to-brain metastasis
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii5, https://doi.org/10.1093/noajnl/vdab070.020
NGMA-6. Quantitative MGMT Promoter Methylation Index Indicates Non-Linear, Prognostic Effect in Glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii5, https://doi.org/10.1093/noajnl/vdab070.021
Final Category: Omics in Molecular Pathology and Tumor Classification
OPTC-1. Proteomic analysis of genetically stratified low-grade meningioma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii6, https://doi.org/10.1093/noajnl/vdab070.022
OPTC-2. Identification of enriched genes and pathways associated to hypoxia induced migration in patient-derived glioma stem cell lines by RNAseq
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii6, https://doi.org/10.1093/noajnl/vdab070.023
OPTC-3. Differential Synapse-Related Gene Expression Identifies Glioma Subtypes and Predicts Prognosis
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii6, https://doi.org/10.1093/noajnl/vdab070.024
OPTC-4. Bioinformatic analysis of COLXIα1 gene expression and its alternative splicing regulation in Paediatric Diffuse Intrinsic Pontine Gliomas (DIPGs)
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii6, https://doi.org/10.1093/noajnl/vdab070.025
OPTC-5. Molecular signatures of podoplanin expressing glioblastoma cell subsets with putative role in cancer associated thrombosis and microthrombosis
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii7, https://doi.org/10.1093/noajnl/vdab070.026
Final Category: Omics of Response to Therapy
OMRT-1. Cannabidiol converts NFKB into a tumor-suppressor in glioblastoma with defined antioxidative properties
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii7, https://doi.org/10.1093/noajnl/vdab070.027
OMRT-2. Liquid biopsy for patient stratification and monitoring of dacomitinib clinical trial in patients with EGFR amplified recurrent glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii7, https://doi.org/10.1093/noajnl/vdab070.028
OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii7–ii8, https://doi.org/10.1093/noajnl/vdab070.029
OMRT-5. Therapy-induced reprogramming drives glioma vascular transdifferentiation and recurrence
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii8, https://doi.org/10.1093/noajnl/vdab070.030
OMRT-6. Optimizing MDM2 inhibition for the treatment of high-grade glioma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii8, https://doi.org/10.1093/noajnl/vdab070.031
OMRT-7. Angiogenesis inhibitors strongly synergize with therapeutics targeting tumor metabolism
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii8, https://doi.org/10.1093/noajnl/vdab070.032
OMRT-8. Precision targeting of cellular pathways with complementary diagnostics
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii8, https://doi.org/10.1093/noajnl/vdab070.033
OMRT-9. Effect of Pre-Operative Stereotactic Radiosurgery on Brain Metastasis: Analysis of DNA and RNA Genomic Profiles from Phase-II Clinical Trial NCT03398694
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii8–ii9, https://doi.org/10.1093/noajnl/vdab070.034
OMRT-11. The effect of microenvironment on glioblastoma stem cells therapeutic resistance
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii9, https://doi.org/10.1093/noajnl/vdab070.035
OMRT-12. Nanoparticle-based CRISPR-Cas9 delivery for anti-glioblastoma immunotherapy
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii9, https://doi.org/10.1093/noajnl/vdab070.036
OMRT-13. Delivery of Ubidecarenone (BPM 31510) to mitochondria effectuates metabolic reprogramming and redox activated apoptosis in Glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii9, https://doi.org/10.1093/noajnl/vdab070.037
OMRT-14. Small molecule circadian clock compounds exhibit potential as a novel therapy paradigm for glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii9, https://doi.org/10.1093/noajnl/vdab070.038
OMRT-15. Multidisciplinary management of non-small cell lung cancer patients with leptomeningeal metastasis in the TKI era
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii10, https://doi.org/10.1093/noajnl/vdab070.039
Final Category: Omics of Tumor Evolution and Heterogeneity
OTEH-1. Alternative RNA splicing modulates composition of ribosomes and determines spatial phenotype of glioblastoma cells
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii10, https://doi.org/10.1093/noajnl/vdab070.040
OTEH-2. High-dimensional analysis of spatial immune cell heterogeneity in glioblastoma reveals differences between contrast-enhancing and non-contrast-enhancing tumor rims
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii10, https://doi.org/10.1093/noajnl/vdab070.041
OTEH-3. Targeted Gene-Expression analysis during malignant transformation in primary and secondary malignant meningioma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii10–ii11, https://doi.org/10.1093/noajnl/vdab070.042
OTEH-4. Deeper insight into intratumoral heterogeneity by MRI and PET-guided stereotactic biopsies from glioblastoma patients
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii11, https://doi.org/10.1093/noajnl/vdab070.043
OTEH-5. Characterization of long-non coding RNA associated ceRNA network hub gene involved in glioblastoma multiforme lipid metabolism
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii11, https://doi.org/10.1093/noajnl/vdab070.044
OTEH-6. Algorithmic approach to characterize post-treatment recurrent glioma using RNA sequencing and quantitative histopathology
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii11, https://doi.org/10.1093/noajnl/vdab070.045
OTEH-7. Molecular characterization of tumor stiffness in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii11–ii12, https://doi.org/10.1093/noajnl/vdab070.046
OTEH-8. Pathway-based approach reveals sensitivity to radiation when targeting E2F1 in Glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii12, https://doi.org/10.1093/noajnl/vdab070.047
OTEH-9. scRNA sequencing of proneural GBM avatar model reveals acquisition of oncogenic transcriptional programming and infers a developmental path towards a genomically unstable state
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii12, https://doi.org/10.1093/noajnl/vdab070.048
OTEH-10. Evolutionary trajectory of epigenomic of gliomas
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii12, https://doi.org/10.1093/noajnl/vdab070.049
OTEH-11. Single Cell RNA Sequencing to identify cellular heterogeneity with in Pituitary Adenomas
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii12–ii13, https://doi.org/10.1093/noajnl/vdab070.050
OTEH-12. Assessing Adaptive Responses to Loss of Extrachromosomal DNA Amplification
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii13, https://doi.org/10.1093/noajnl/vdab070.051
Final Category: Omics of Tumor Microenvironment
OTME-1. TAMEP are brain tumor parenchymal cells controlling neoplastic angiogenesis and progression
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii13, https://doi.org/10.1093/noajnl/vdab070.052
OTME-2. Regulation of chromatin accessibility in the hypoxic tumor microenvironment of glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii13, https://doi.org/10.1093/noajnl/vdab070.053
OTME-3. Dissection of the role of stromal microenvironment and tumor-TME crosstalk in pediatric brain cancer
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii13–ii14, https://doi.org/10.1093/noajnl/vdab070.054
OTME-4. IDH mutated gliomas promote epileptogenesis via D-2-hydroxyglutarate dependent mTOR hyperactivation
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii14, https://doi.org/10.1093/noajnl/vdab070.055
OTME-5. Meningioma liquid biopsy specimens exhibit contrasting immune-cell landscapes across methylation-subtypes and estimated recurrence risk subgroups
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii14, https://doi.org/10.1093/noajnl/vdab070.056
OTME-6. Deep sequencing reveals heterogeneity of brain metastasis-associated macrophages and microglia and uncovers their cell type-specific functions within the tumor microenvironment
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii14, https://doi.org/10.1093/noajnl/vdab070.057
OTME-7. Cancer - immune cell interactions drive transitions to mesenchymal-like state in glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii14–ii15, https://doi.org/10.1093/noajnl/vdab070.058
OTME-8. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii15, https://doi.org/10.1093/noajnl/vdab070.059
OTME-9. Comprehensive Metabolic Profiling Of high MYC Medulloblastoma Reveals Key Differences Between In Vitro And In Vivo Glucose And Glutamine Usage
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii15, https://doi.org/10.1093/noajnl/vdab070.060
OTME-10. Integrated analysis of human gliomas at the single cell level identifies S100A4 as a novel immunotherapy target
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii15, https://doi.org/10.1093/noajnl/vdab070.061
OTME-11. Characterizing the immunologic context of pediatric brain tumors
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii15, https://doi.org/10.1093/noajnl/vdab070.062
OTME-12. Role of the transsulfuration pathway in glioblastoma invasion
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii15–ii16, https://doi.org/10.1093/noajnl/vdab070.063
OTME-13. Integration of metabolic and transcriptional signatures of glioblastoma invasion reveals extracellular matrix reorganization and vasculature remodeling
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii16, https://doi.org/10.1093/noajnl/vdab070.064
OTME-14. TGF-beta signaling in microtube formation of glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii16, https://doi.org/10.1093/noajnl/vdab070.065
OTME-15. Physical Confinement Induces Diverse Transcriptomic Changes and Chemoresistance in Migrating Glioblastoma Cells
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii16, https://doi.org/10.1093/noajnl/vdab070.066
OTME-16. Polio virotherapy of murine brain tumors causes microglia/macrophage proliferation and inflammation that is potentiated by immune checkpoint blockade
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii17, https://doi.org/10.1093/noajnl/vdab070.067
OTME-17. Single cell characterization of the immune microenvironment of melanoma brain and leptomeningeal metastases
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii17, https://doi.org/10.1093/noajnl/vdab070.068
OTME-18. Targeted CRISPR/Cas9 gene-editing regulates the brain tumor environment
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii17, https://doi.org/10.1093/noajnl/vdab070.069
OTME-19. Regula Regulation of Gliomagenesis and Stemness Through Acid Sensor ASIC1a
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii17, https://doi.org/10.1093/noajnl/vdab070.070
OTME-20. Chitinase-3-like-1(CHI3L1) Protein Complexes Regulate the immunosuppressive Microenvironment in Glioblastoma
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Pages ii17–ii18, https://doi.org/10.1093/noajnl/vdab070.071
OTME-21. The role of Glioblastoma associated mesenchymal stem cells in immune suppression
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii18, https://doi.org/10.1093/noajnl/vdab070.072
OTME-22. Bioinformatic evaluation of ECM molecules and angiogenic associate genes in diffuse midline glioma (DMG): mapping the tumour microenvironment
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii18, https://doi.org/10.1093/noajnl/vdab070.073
OTME-23. Single-cell transcriptomic and epigenomic immune landscape of isocitrate dehydrogenase stratified human gliomas
Neuro-Oncology Advances, Volume 3, Issue Supplement_2, July 2021, Page ii18, https://doi.org/10.1093/noajnl/vdab070.074
